Filing Details
- Accession Number:
- 0001246360-15-001755
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-08 18:35:08
- Reporting Period:
- 2015-04-06
- Filing Date:
- 2015-04-08
- Accepted Time:
- 2015-04-08 18:35:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
911326 | Synageva Biopharma Corp | GEVA | Biological Products, (No Disgnostic Substances) (2836) | 561808663 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1532219 | Anthony Quinn | 33 Hayden Ave Lexington MA 02421 | Evp, Cmo & Head Of R&D | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-04-06 | 42 | $76.88 | 25,637 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2015-04-06 | 10,000 | $0.95 | 35,637 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2015-04-06 | 9,503 | $23.00 | 45,140 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-04-06 | 29,503 | $93.76 | 15,637 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2015-04-06 | 10,000 | $0.00 | 10,000 | $0.95 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2015-04-06 | 9,503 | $0.00 | 9,503 | $23.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
8,964 | 2019-10-07 | No | 4 | M | Direct | |
20,497 | 2021-12-20 | No | 4 | M | Direct |
Footnotes
- The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c).
- The reporting person is voluntarily reporting this transaction as of 04/06/2015, but the actual transaction took place on 12/31/2014, the last trading day of the option period under the ESPP.
- In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period.
- The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 6, 2015.
- The Stock Option granted the reporting person an option to purchase 101,080 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 08/31/2010, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
- The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.